Genomic Screening: The Mutation and the Mustard Seed

Pliny the Elder, “The Natural History,” in: J. Bostock , ed., (London: Taylor and Francis, 1855): 19:54, available at <http://data.perseus.org/citations/urn:cts:latinLit:phi0978.phi001.perseus-eng1:19.54> (last accessed March 17, 2018).

M.M. Clark et al ., “A Meta-analysis of the Diagnostic Sensitivity and Clinical Utility of Genome Sequencing, Exome Sequencing and Chromosomal Microarray in Children with Suspected Genetic Diseases,” BioRxiv pre-print January 30, 2018, available at <https://doi.org/10.1101/255299> (last visited March 18, 2018); Z. Stark et al., “Meeting the Challenges of Implementing Rapid Genomic Testing in Acute Pediatric Care,” Genetics in Medicine 3 (2018): 1-10.

R.C. Green et al ., “ACMG Recommendations for Reporting of Incidental Findings in Clinical Exome and Genome Sequencing,” Genetics in Medicine 15, no. 7 (2013): 565-574; ACMG Board of Directors, “ACMG Policy Statement: Updated Recommendations Regarding Analysis and Reporting of Secondary Findings in Clinical Genome-scale Sequencing,” Genetics in Medicine 17, no. 1 (2015): 68-69.

L.M. Amendola et al ., “Actionable Exomic Incidental Findings in 6503 Participants: Challenges of Variant Classification,” Genome Research 25, no. 3 (2015): 305-315; S.S. Kalia et al., “Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): a Policy Statement of the American College of Medical Genetics and Genomics,” Genetics in Medicine 19, no. 2 (2017): 249-255.

K.A. Wetterstrand , “DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP),” available at <www.genome.gov/sequencingcosts-data> (last accessed March 17, 2018)

T. Ray , “UCSF Opens Preventive Genomics Clinic to Support Patients After Online Genetic Testing,” Genomeweb February 2, 2018, available at <https://www.genomeweb.com/molecular-diagnostics/ucsf-opens-preventive-genomics-clinic-support-patients-after-online-genetic#.Wq7GiajwaUk> (last accessed March 18, 2018).

A.M. Small , C.J. O’Donnell , and S.M. Damrauer , “Large-Scale Genomic Bio-banks and Cardiovascular Disease,” Current Cardiology Reports 20, no.4 (2018): 1-9.

Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital, available at <http://mrctcenter.org/projects/return-of-individual-results/> (last accessed March 17, 2018).

M. Heger , “Large-Scale Sequencing Projects Navigate Grey Area Between Research, Clinical Testing,” Genomeweb, January 26, 2018, available at <https://www.genomeweb.com/sequencing/large-scale-sequencing-projects-navigate-grey-area-between-research-clinical-testing#.Wq7BDqjwaUk> (last accessed March 17, 2018).

U.S. Preventive Services Task Force (USPSTF), “Final Recommendation Statement: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing,” December 2013, available at <https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing (last accessed March 17, 2018).

A.H. Buchanan et al ., “Early Cancer Diagnoses Through BRCA1/2 Screening of Unselected Adult Biobank Participants,” Genetics in Medicine 20, no. 5 (2018): 554-558.

H.G. Welch and O.W. Brawley , “Scrutiny-Dependent Cancer and Self-fulfilling Risk Factors,” Annals of Internal Medicine 168, no. 2 (2018): 143-144.

B.P. Trivedi , “Is Health Care Ready for Routine DNA Screening? A Massive New Trial Will Find Out,” ScienceMag October 26, 2017, available at <http://www.sciencemag.org/news/2017/10/health-care-ready-routine-dna-screening-massive-new-trial-will-find-out> (last accessed March 18, 2018).

R. Fossey et al ., “Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience,” Journal of Personalized Medicine 8, no. 2 (2018): 1-18.

Personal communication to author from Deborah Miller, Adam Buchanan, Amy Sturm, and David Ledbetter of Geisinger Health System, March 6, 2018.

J.M. Hoskovec et al ., “Projecting the Supply and Demand for Certified Genetic Counselors: a Workforce Study,” Journal of Genetic Counseling 27, no. 1 (2018): 16-20.

C. Curtin , “Web-Based Return of Genetic Testing Results Shows Promise in Study,” GenomeWeb, February 7, 2018, available at <https://www.genomeweb.com/sequencing/web-based-return-genetic-testing-results-shows-promise-study#.Wq69xajwaUk> (last accessed March 18, 2018).

Fossey, supra note 14.

D. Seegal , “Less May be More: Reminiscences on the Educational Impact of Some Pertinent and Pithy Remarks by my Teachers,” Journal of Chronic Diseases 16, no. 5 (1963): 441-444.

H.L. Rehm et al ., “ACMG Clinical Laboratory Standards for Next-Generation Sequencing,” Genetics in Medicine, September 15, no. 9 (2013): 733-747.

S. Richards et al ., “Standards and Guidelines for the Interpretation of Sequence Variants: a Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology,” Genetics in Medicine 17, no. 5 (2015): 405-424.

Kalia et al., supra note 4.

M.C. Adams , J.P. Evans , G.E. Henderson , J.S. Berg , “The Promise and Peril of Genomic Screening in the General Population,” Genetics in Medicine 18, no. 6 (2016): 593-599.

T.M. Morgan , “Genetic Testing for Rare and Undiagnosed Diseases,” in: S.P. David , ed., Genomic and Precision Medicine (London: Academic Press, 2017): 59-71.

R.Q. Yang et al ., “New Population-based Exome Data Question the Pathogenicity of Some Genetic Variants Previously Associated with Marfan Syndrome,” BMC Genetics 15, no. 74 (2014): 1-8.

K.A. Groth et al ., “Difficulties in Diagnosing Marfan Syndrome Using Current FBN1 Databases,” Genetics in Medicine 18, no. 1 (2016): 98-102; K.A. Groth et al., “Evaluating the Quality of Marfan Genotype-phenotype Correlations in Existing FBN1 Databases,” Genetics in Medicine 19, no. 7 (2017): 772-777.

J. De Backer et al ., “Utility of Molecular Analyses in the Exploration of Extreme Intrafamilial Variability in the Marfan syndrome,” Clinical Genetics 72, no. 3 (2007): 188-198.

L. Bastarache et al ., “Phenotype Risk Scores Identify Patients with Unrecognized Mendelian Disease Patterns,” Science 359, no. 6381 (2018): 1233–1239.

A.E. Prince , “Prevention for Those Who Can Pay: Insurance Reimbursement of Genetic-Based Preventive Interventions in the Liminal State Between Health and Disease,” Journal of Law and Bioscience 2, no. 2 (2015): 365-395.

Trivedi, supra note 13.

J.P. Ackerman et al ., “The Promise and Peril of Precision Medicine: Phenotyping Still Matters Most,” Mayo Clinic Proceedings 91, no. 11 (2016): 1606-1616.

M. Ashford , “LawSeq Effort Aims to Clarify Issues of Consent, Standards, and Liability in Genomic Medicine,” Genomeweb, July 5, 2016, available at <https://www.genomeweb.com/sequencing/lawseq-effort-aims-clarify-issues-consent-standards-and-liability-genomic-medicine#.Wq6Jj6jwaUk> (last visited March 18, 2018).

J.L. Vassy et al ., “The Impact of Whole-Genome Sequencing on the Primary Care and Outcomes of Healthy Adult Patients: A Pilot Randomized Trial,” Annals of Internal Medicine 167 (2017): 159-169.

M.L. Rothstein , “The Case against Precipitous, Population-Wide, Whole-Genome Sequencing” Journal of Law, Medicine & Ethics 40, no. 3 (2012): 682-689.

M.J. Khoury , “No Shortcuts on the Long Road to Evidence-Based Genomic Medicine,” JAMA 318, no. 1 (2017): 27-28.